预约演示
更新于：2025-07-02
Edaravone/Dexborneol
依达拉奉右莰醇
更新于：2025-07-02
概要
基本信息
原研机构 |
在研机构 |
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 中国 (2020-07-29), |
最高研发阶段(中国)批准上市 |
特殊审评突破性疗法 (美国)、突破性疗法 (中国)、特殊审批 (中国) |
登录后查看时间轴
结构/序列
分子式C10H18O |
InChIKeyDTGKSKDOIYIVQL-QXFUBDJGSA-N |
CAS号464-45-9 |
查看全部结构式(2)
关联
37
项与 依达拉奉右莰醇 相关的临床试验NCT06674460
Treatment of Acute Ischemic Stroke with Edaravone Dexborneol Sublingual Tablets in Small Vessel Disease: a Randomized, Double-Blind, Placebo-Controlled Study
ChiCTR2400092364
Clinical efficacy of edaravone dexborneol combined with hyperbaric oxygen therapy (HBOT) in the treatment of acute ischemic stroke based on real-world data - A study on clinical efficacy of edaravone dexborneol combined with hyperbaric oxygen therapy (HBOT) in the treatment of acute ischemic stroke
NCT06645522
Safety and Efficacy of Edaravone Dexborneol for Acute Ischemic Stroke: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial
100 项与 依达拉奉右莰醇 相关的临床结果
登录后查看更多信息
100 项与 依达拉奉右莰醇 相关的转化医学
登录后查看更多信息
100 项与 依达拉奉右莰醇 相关的专利（医药）
登录后查看更多信息
50
项与 依达拉奉右莰醇 相关的文献（医药）2025-05-01PHYTOMEDICINE
Edaravone dexborneol exerts anti-epileptic effects on rodent temporal lobe epilepsy by promoting NMDAR deactivation and inhibiting oxidative stress
Article
作者: Li, Yiqian ; Pan, Lechen ; Xu, Huiqin ; Xie, Chenglong ; Huang, Wenting ; Wang, Xinshi ; Li, Yuqian ; Qiu, Wanhua ; Chen, Roumeng ; Lin, Li ; Xu, Yuchen ; Li, Peijun ; Guo, Ang ; Tan, Tao
BACKGROUND:
Disease-modifying treatments with anti-epileptic effects are currently unavailable and urgently required for temporal lobe epilepsy (TLE). Combined therapy targeting multiple mechanisms may offer a promising anti-epileptic strategy, given the complex processes underlying epileptogenesis.
PURPOSE:
This study evaluates the effects of Edaravone Dexbroneol, a combination of Edaravone and Dexborneol in 4:1, on rat and mouse TLE models and an in vitro epileptiform activity model.
METHODS:
The Pilocarpine-induced rat TLE model and the Kainic acid-induced mouse TLE model were used to assess the in vivo effect of Edaravone and/or Dexbornel. Primary neurons were utilized to evaluate the in vitro effect of drugs using calcium imaging, electrophysiological and biochemical analyses, as well as RNA sequencing.
RESULTS:
Treatment of Edaravone Dexbornel during the latent period significantly alleviated epileptic seizures in rodents, mitigated cognitive impairment, and inhibited neuronal loss and astrocytic activation. In vitro, Edaravone Dexborneol inhibited the action potentials and protected primary hippocampal neurons from Mg2+-free-induced neurite injury. All these effects were significantly more pronounced in the group treated with the Edaravone Dexborneol mixture compared to either drug used individually. Furthermore, Edaravone can significantly inhibit Mg2+-free-induced calcium oscillations in primary neurons, probably by promoting the deactivation of NMDA receptors. RNA sequencing and RT-PCR analysis revealed that synergetic regulation of lipid metabolism, oxidative stress, apoptosis, and calcium signaling probably underlay the neuroprotective effect of Edaravone Dexbornel on epileptic neurons.
CONCLUSION:
Edaravone Dexborneol exhibits antiepileptic effects and may fill the gap in disease-modifying treatments for TLE.
2025-02-01JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY
Effect of edaravone dexborneol combined with interventional thrombectomy on nerve function, cerebral hemodynamics, and serum levels of serum amyloid A, lipoprotein-associated phospholipase A2, and soluble CD40 ligand in elderly patients with ischemic stroke.
Article
作者: Zhou, X ; Shu, Z G ; Li, D Z ; Liu, S C
This study investigated the effect of edaravone dexborneol (ED) combined with interventional thrombectomy in the treatment of ischemic stroke (IS) in the elderly and its effects on nerve function, cerebral hemodynamic status, and levels of serum amyloid A (SAA), lipoprotein-associated phospholipase A2 (LP-PLA2), and soluble CD40 ligand (sCD40L). One hundred elderly patients with IS were divided into the control group and observation group by random number table method. The control group received conventional treatment after interventional thrombectomy, and the observation group received conventional treatment and ED treatment after interventional thrombectomy. After 14 days of treatment, the therapeutic effect was evaluated according to the National Institutes of Health Stroke Scale (NIHSS). Neurological function, serum brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neuron-specific enolase (NSE), cerebral haemodynamics, indices of oxidative stress, and serum levels of SAA, LP-PLA2, and sCD40L before and after treatment in both groups were compared. The total effective rate of clinical efficacy was higher and the NIHSS score was lower in the observation group than in the control group (P<0.05). The observation group exhibited higher mean blood velocity and mean blood flow, alongside lower characteristic impedance and dynamic resistance, compared to the control group (P<0.05). SAA, LP-PLA2, and sCD40L in the observation group were lower than those in the control group (P<0.05). BDNF, NGF, and SOD in the observation group were higher than those in the control group, and NSE, MDA, and NEF were lower (P<0.05). ED combined with interventional thrombectomy in the treatment of IS in the elderly can improve nerve function, alleviate oxidative stress reaction, reduce levels of SAA, LP-PLA2, and sCD40L, and alleviate inflammatory response.
2024-12-01Stroke and vascular neurology
Rationale and design of Treatment of Acute Ischaemic Stroke with Edaravone Dexborneol II (TASTE-2): a multicentre randomised controlled trial
Article
作者: Dong, Qiang ; Wang, Yongjun ; Gu, Hong-Qiu ; Yang, Yi ; Xu, Anding ; Wang, Feng ; Wang, Ning ; Wang, Chunjuan
Background:
Edaravone dexborneol is believed to be a novel cytoprotective drug, demonstrating a synergistic combination of antioxidative and anti-inflammatory properties in animal models. The Treatment of Acute Ischaemic Stroke with Edaravone Dexborneol (TASTE) trial demonstrated its superior efficacy over edaravone alone for acute ischaemic stroke (AIS) patients. However, its efficacy in individuals undergoing endovascular therapy (EVT) remains uncertain.
Aim:
To clarify the rationale and design of the TASTE II (TASTE-2) trial.
Design:
The TASTE-2 is a multicentre, double-blind, randomised, placebo-controlled trial designed to evaluate the efficacy and safety of edaravone dexborneol in patients with AIS and large-vessel occlusion in the anterior circulation. The eligible participants, presenting with a National Institute of Health Stroke Scale score between 6 and 25 (range 0–42, with larger values suggesting severe neurological dysfunction) and an Alberta Stroke Program Early Computed Tomography Score ranging from 6 to 10 (range 0–10, with smaller values suggesting larger infarction) within the initial 24 hours after symptom onset, will be randomly allocated to either the edaravone dexborneol group or the placebo group in equal proportions prior to thrombectomy. The treatment will be continuously administered for a duration of 10–14 days. A follow-up period of 90 days will be implemented for all participants.
Study outcomes:
The primary efficacy outcome is defined as achieving favourable functional independence, measured by a modified Rankin Scale of 0–2 at 90 days. The primary safety outcome focuses on the incidence of serious adverse events.
Discussion:
The TASTE-2 trial will provide evidence to determine whether the administration of edaravone dexborneol in AIS patients undergoing EVT could yield significant improvements in neurological function.
100 项与 依达拉奉右莰醇 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 雄激素不敏感综合征 | 临床3期 | - | 2023-12-28 | |
| 认知功能障碍 | 临床2期 | 中国 | 2024-04-08 | |
| 脑出血 | 临床2期 | - | 2021-03-01 | |
| 高血压脑病 | 临床2期 | - | 2021-03-01 | |
| 颅内出血 | 临床1期 | 美国 | 2018-10-25 | |
| 肌萎缩侧索硬化 | 临床申请 | 美国 | - | |
| 认知障碍 | 临床申请 | 美国 | - | |
| 神经炎症 | 临床前 | 中国 | 2024-03-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | - | 廠醖簾餘獵淵鏇鏇遞鑰(鑰衊製鑰醖觸淵餘鬱蓋): unadjusted odds ratio = 1.37 (95% CI, 0.76 ~ 2.44), P-Value = 0.29 | 不佳 | 2025-03-10 | |||
Placebo | |||||||
N/A | - | 衊製襯憲壓夢製艱觸壓(獵選簾衊壓顧選膚淵願) = 醖鏇蓋夢壓蓋顧醖積艱 鹽廠衊範遞膚願淵襯繭 (選鏇膚選壓構齋齋鏇廠 ) | 积极 | 2025-01-30 | |||
No Edaravone Dexborneol | 衊製襯憲壓夢製艱觸壓(獵選簾衊壓顧選膚淵願) = 範鹹淵鏇淵膚夢餘觸鏇 鹽廠衊範遞膚願淵襯繭 (選鏇膚選壓構齋齋鏇廠 ) | ||||||
N/A | 4,684 | 鑰鏇簾積顧壓襯壓憲窪(築餘廠廠鑰膚築廠膚齋): adjusted common odds ratio = 1.02 (95% CI, 1.02 ~ 1.64), P-Value = 1.30 | 积极 | 2025-01-30 | |||
No Edaravone Dexborneol | |||||||
临床3期 | 914 | 積膚顧製鏇築襯遞鹽醖(願範遞膚夢餘遞簾簾鹹) = 憲醖糧鹹顧鹽積簾醖範 蓋願製繭糧製壓齋製獵 (醖遞構構觸鏇齋膚願鏇 ) 更多 | 积极 | 2024-02-19 | |||
Placebo | 積膚顧製鏇築襯遞鹽醖(願範遞膚夢餘遞簾簾鹹) = 簾襯夢鑰鏇繭膚顧簾網 蓋願製繭糧製壓齋製獵 (醖遞構構觸鏇齋膚願鏇 ) 更多 | ||||||
临床3期 | - | 簾廠築襯鬱憲齋憲壓襯(鏇選窪觸糧鬱繭壓簾鏇) = 初步分析显示，相对于安慰剂， 先必新舌下片显著改善AIS患者治疗后神经功能恢复及独立生活能力，达到预期疗效终点 鏇繭獵觸鏇遞選憲鑰鑰 (製築憲鑰鹽憲鏇積製繭 ) 达到 | 积极 | 2022-12-01 | |||
Placebo | |||||||
NEWS 人工标引  | N/A | 94 | 製選餘糧範蓋鏇製積範(網積齋繭廠壓願範窪顧) = 衊簾淵構築遞襯網觸憲 糧網願鑰糧窪襯膚選鏇 (積鹹網餘衊餘鹹繭艱鏇, 4.11) 更多 | 积极 | 2022-05-06 | ||
製選餘糧範蓋鏇製積範(網積齋繭廠壓願範窪顧) = 糧鹹餘觸鬱簾廠壓範憲 糧網願鑰糧窪襯膚選鏇 (積鹹網餘衊餘鹹繭艱鏇, 2.15) 更多 | |||||||
临床3期 | 1,165 | 築鑰選簾鹽襯糧膚夢糧(簾鬱糧選積憲餘選獵齋) = 範衊簾憲廠糧窪窪選網 憲觸艱壓築廠獵繭憲積 (範廠夢構蓋蓋獵鏇繭願 ) 更多 | 优效 | 2021-03-01 | |||
築鑰選簾鹽襯糧膚夢糧(簾鬱糧選積憲餘選獵齋) = 積膚廠蓋憲觸憲夢壓蓋 憲觸艱壓築廠獵繭憲積 (範廠夢構蓋蓋獵鏇繭願 ) | |||||||
临床2期 | 385 | 選壓艱蓋蓋鏇齋廠積蓋(蓋衊鏇壓憲鑰糧選襯窪): P-Value = 0.6799 更多 | 积极 | 2019-04-22 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用